000 04521cam a2200397Ii 4500
001 94808
003 ES-MaUEC
005 20230102112632.0
006 m o d
007 cr cnu|||unuuu
008 161102t20162017si o 000 0 eng d
020 _a9789811024160
_q(electronic bk.)
020 _a9811024162
_q(electronic bk.)
020 _z9789811024153
_q(print)
020 _z9811024154
035 _a(OCoLC)961910198
_z(OCoLC)962127673
040 _aN$T
_cN$T
_dEBLCP
_dGW5XE
_dIDEBK
_dN$T
_dOCLCF
_dYDX
_dUAB
_dIOG
_dMERER
_dESU
_dZ5A
_dOCLCQ
_dJBG
_dIAD
_dICN
_dOTZ
_dOCLCQ
_dU3W
_dES-MaUEC
_bspa
050 4 _aRC848.H425
_b2017 EB
245 0 0 _aHepatitis C virus treatment :
_bhighly effective therapy with direct acting antivirals and associated viral resistance
_cKazuaki Chayama, editor.
264 1 _aSingapore
_bSpringer International Publishing
_c2016
264 4 _c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aPreface; Contents; 1: Treatment of€Chronic Hepatitis C with€the€First-Generation Protease Inhibitor Telaprevir: Its Efficacy and€Resistance Mutations; 1.1 Introduction; 1.2 Protease Inhibitors; 1.3 Telaprevir; 1.3.1 Clinical Trial Results; 1.3.2 Triple Therapy in€Clinical Practice; 1.3.3 Triple Therapy for€Genotype 2 Patients; 1.3.4 Telaprevir Treatment and€Resistance Mutations; 1.3.5 The Current Role of€Triple Therapy with€TVR; 1.4 Conclusion; References; 2: Features of€the€Second Wave of€the€First Generation Protease Inhibitors: Effect and€Tolerance; 2.1 Introduction.
505 8 _a2.2 Simeprevir2.3 Asunaprevir; 2.4 Vaniprevir; 2.5 Paritaprevir; 2.6 Conclusion; References; 3: The Efficacy of€Daclatasvir Plus Asunaprevir Combination Therapy with€Chronic Hepatitis; 3.1 Introduction; 3.2 DAA Mechanisms of€Action; 3.2.1 Protease Inhibitors: Asunaprevir; 3.2.2 NS5A Inhibitors: Daclatasvir; 3.3 Phase 3 Results of€Daclatasvir Plus€Asunaprevir Therapy in€Japan; 3.3.1 Treatment Results in€Patients Who Did Not Respond to€IFN-Based Therapy and€Patients Who Are IFN-ƯIneligible/Intolerant; 3.3.2 Treatment Results in€Treatment-Naïve Patients and€Prior Interferon Relapsers.
505 8 _a3.4 Appearance of€Resistance-Associated Variants in€Patients with€Virologic Failure3.5 Treatment Results After Approval of€the€Therapy; 3.6 Indications and€Cautions; 3.7 Conclusion; References; 4: Resistance-Associated Variants in€the€NS5A Region of€HCV and€Methods for€the€Detection; 4.1 Characteristics of€HCV-NS5A and€the€Action Sites of€NS5A Inhibitors; 4.2 Assay Systems to€Detect and€Quantify NS5A-RAVs of€Genotype-1b HCV; 4.3 Significance of€Amino Acid Mutations in€the€NS5A Region in€Patients with€HCV Infection; 4.4 Therapeutic Efficacies of€DAAs and€NS5A Polymorphisms; References.
505 8 _a5: Detection of€Antiviral Drug-Resistant Variants in€Chronic Hepatitis C by Deep Sequencing5.1 Introduction; 5.2 Deep Sequencing Analysis of€RAVs and€the€Aim of€RAV Analysis; 5.3 Interferon-Based DAA Therapy; 5.3.1 TVR/PEG-IFN/RBV Combination Therapy; 5.3.2 SMV/PEG-IFN/RBV Combination Therapy; 5.4 Interferon-Free DAA Therapy; 5.5 Conclusions; References; 6: Incidence and€Characteristics of€Naturally Occurring Drug-Resistant Hepatitis C Virus Strains; 6.1 Introduction; 6.2 Naturally Occurring Protease Inhibitor-Resistant Variants.
505 8 _a6.3 Naturally Occurring NS5A Inhibitor-Resistant Variants6.4 Naturally Occurring NS5B Inhibitor-Resistant Variants; 6.5 Conclusion; References; 7: Treatment Effects and Resistance-Associated Variants of Sofosbuvir Regimen for Japanese Patients with Chronic Hepatitis C Virus Genotypes 1 and 2; 7.1 The Mechanism of€Action of€Sofosbuvir and€a€Note of€Caution; 7.2 Characteristics of€Sofosbuvir; 7.3 Sofosbuvir/Ribavirin Therapy for€Genotype 2; 7.3.1 Study Design and€Patients Characteristics; 7.3.2 Efficacy and€Safety; 7.3.3 NS5B RAVs and€Sofosbuvir/Ribavirin Therapy.
650 7 _aHepatitis C
_2embne
_0(OCoLC)fst00955217
_0
_9158778
700 1 _aChayama, Kazuaki,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-2416-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aSpringer_Medicine_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c94808
_d94808
_x1